Generex Biotechnology Corp Stock Net Income
| GNBTDelisted Stock | USD 0.0001 0.00 0.00% |
Generex Biotechnology Corp fundamentals help investors to digest information that contributes to Generex Biotechnology's financial success or failures. It also enables traders to predict the movement of Generex OTC Stock. The fundamental analysis module provides a way to measure Generex Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Generex Biotechnology otc stock.
Generex |
Generex Biotechnology Corp OTC Stock Net Income Analysis
Generex Biotechnology's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Generex Biotechnology Net Income | (33.34 M) |
Most of Generex Biotechnology's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Generex Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Generex Biotechnology Corp reported net income of (33.34 Million). This is 109.77% lower than that of the Biotechnology sector and 147.59% lower than that of the Health Care industry. The net income for all United States stocks is 105.84% higher than that of the company.
Generex Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Generex Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Generex Biotechnology could also be used in its relative valuation, which is a method of valuing Generex Biotechnology by comparing valuation metrics of similar companies.Generex Biotechnology is currently under evaluation in net income category among related companies.
Generex Fundamentals
| Return On Equity | -17.73 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (49.52) % | |||
| Current Valuation | 7.68 M | |||
| Shares Outstanding | 118.45 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Number Of Shares Shorted | 211.98 K | |||
| Price To Earning | 5.59 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 2.66 M | |||
| Gross Profit | 2.08 M | |||
| EBITDA | (26.12 M) | |||
| Net Income | (33.34 M) | |||
| Cash And Equivalents | 1.68 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 499.66 K | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.48) X | |||
| Cash Flow From Operations | (6.12 M) | |||
| Short Ratio | 1.73 X | |||
| Earnings Per Share | (0.37) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 15 | |||
| Beta | -0.0623 | |||
| Market Capitalization | 71.07 K | |||
| Total Asset | 45.38 M | |||
| Retained Earnings | (373.34 M) | |||
| Working Capital | (8.68 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 8.73 M | |||
| Z Score | -11.2 | |||
| Net Asset | 45.38 M |
About Generex Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Generex Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Generex Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Generex Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Generex Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Generex Biotechnology's short interest history, or implied volatility extrapolated from Generex Biotechnology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Generex OTC Stock
If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |